This is an observational study to compare the utility of the novel aMRI approach in human brain to the standard of care imaging approach for diagnosing and assessing glioma. Tumor cells have altered metabolism compared to normal cells.This makes metabolic activity imaging useful for diagnosing and assessing neurological disease. However, current options for metabolic activity imaging are limited. Metabolic activity imaging is primarily conducted using positron emission tomography (PET) with a radioactive tracer called fludeoxyglucose F-18 (¹⁸FDG). A PET scan is a procedure in which a small amount of radioactive glucose (¹⁸FDG) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. PET imaging is very expensive and is usually much less available than other imaging techniques such as magnetic resonance imaging (MRI). MRI uses radiofrequency waves and a strong magnetic field to provide clear and detailed pictures of internal organs and tissues. While MRI is more available than PET, it isn't as useful in evaluating metabolic activity. Unlike standard MRI, the aMRI approach uses new ways of analyzing MRI images that provides information about tumor cell metabolic activity. Via direct comparison with a standard metabolic imaging approach, ¹⁸FDG PET, this clinical trial will assess the validity of aMRI as a metabolic imaging approach for evaluating neurological disease in patients with glioma.

Start Date11 Dec 2023

Sponsor / Collaborator

OHSU Knight Cancer Institute

[+1]

CTRI/2022/09/045350 / Not yet recruitingNot Applicable

GLUCOSAMINE AS AN ADJUVANT IN MANAGMENT OF TEMPOROMANDIBULAR DISORDERS :A RANDOMIZED CLINICAL TRIAL

Start Date12 Sep 2022

Sponsor / Collaborator-

NCT04665804 / CompletedNot ApplicableIIT

Effects of Creatine Supplementation as Compared to Glucosamine/Chondroitin Sulfate Supplementation in Addition to Exercise and Physical Therapy in the Management of Knee Osteoarthritis.

Osteoarthritis (OA) is one of the most common joint disorders, affecting not only the joints but also the surrounding muscles, which become weak. Resistance exercise reduces pain and improves function in patients with OA of the knee. Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used by patients with OA to reduce pain and thereby maintain the ability to perform daily activities. However, there is accumulating evidence for a negative effect of NSAIDs, thus many patients with OA are treated with dietary supplementations such as glucosamine and chondroitin sulfate, and some studies show a beneficial effects on cartilage and pain. However, their effect on OA symptoms and cartilage remains controversial. On the other hand creatine supplementation has also been observed to show promising effects when combined with resistance training exercise in the elderly, but the evidence is limited in terms of knee osteoarthritis. For this reason the purpose of this study is to determine the effects of creatine supplementation as compared to glucosamine/chondroitin sulfate in the management of knee osteoarthritis when combined with resistance training exercise.

Start Date10 Jun 2020

Sponsor / Collaborator

Foundation University Islamabad

100 Clinical Results associated with Glucosamine Hydrochloride

100 Translational Medicine associated with Glucosamine Hydrochloride

100 Patents (Medical) associated with Glucosamine Hydrochloride

2,661

Literatures (Medical) associated with Glucosamine Hydrochloride

01 Mar 2024·Biochimie

At the outer part of the active site in Trypanosoma cruzi glucokinase: The role of phenylalanine 337

Article

Author: Alvarez, Beda E ; Buechner, Gregory S ; Daneshian, Leily ; Kearns, Sean P ; Abiskaroon, Brendan ; Millington, Matthew E ; Chruszcz, Maksymilian ; Carey, Shane M ; D'Antonio, Edward L

The hole mutagenesis approach was used to interrogate the importance of F337 in Trypanosoma cruzi glucokinase (TcGlcK) in order to understand the complete set of binding interactions that are made by d-glucosamine analogue inhibitors containing aromatic tail groups that can extend to the outer part of the active site. An interesting inhibitor of this analogue class includes 2-N-carboxybenzyl-2-deoxy-d-glucosamine (CBZ-GlcN), which exhibits strong TcGlcK binding with a K_i of 710 nM. The residue F337 is found at the outer part of the active site that stems from the second protein subunit of the homodimeric assembly. In this study, F337 was changed to leucine and alanine so as to diminish phenylalanine's side chain size and attenuate intermolecular interactions in this region of the binding cavity. Results from enzyme - inhibitor assays revealed that the phenyl group of F337 made dominant hydrophobic interactions with the phenyl group of CBZ-GlcN as opposed to π - π stacking interactions. Moreover, enzymatic activity assays and X-ray crystallographic experiments indicated that each of these site-directed mutants primarily retained their activity and had high structural similarity of their protein fold. A computed structure model of T. cruzi hexokinase (TcHxK), which was produced by the artificial intelligence system AlphaFold, was compared to an X-ray crystal structure of TcGlcK. Our structural analysis revealed that TcHxK lacked an F337 counterpart residue and probably exists in the monomeric form. We proposed that the d-glucosamine analogue inhibitors that are structurally similar to CBZ-GlcN may not bind as strongly in TcHxK as they do in TcGlcK because of absent van der Waals contact from residue side chains.

01 Feb 2024·The journals of gerontology. Series A, Biological sciences and medical sciences

No Associations Between Glucosamine Supplementation and Dementia or Parkinson’s Disease: Findings From a Large Prospective Cohort Study

Article

Author: Fu, Jiaying ; Li, Haitao ; Ai, Baozhuo ; Lin, Hualiang ; Cai, Miao ; Zhang, Zilong ; Chen, Lan

Abstract:

Background:

We investigated the associations between habitual use of glucosamine and incident dementia and Parkinson’s disease in a population-based cohort.

Methods:

Using the UK Biobank data, we included around 0.29 million middle- to old-aged participants free of dementia or Parkinson’s disease at baseline. Glucosamine supplementation was measured by questionnaire at baseline. Some participants additionally answered 1–5 rounds of 24-hour dietary recalls afterwards, particularly 112 243 participants (for dementia) and 112 084 (for Parkinson’s disease). Incident cases of dementia and Parkinson’s disease were identified through linkage to health administrative data sets. We examined the associations of glucosamine supplementation with incident dementia and Parkinson’s disease using Cox proportional-hazards regression models with adjustment for various covariates.

Results:

During the study period (median follow-up: 9.1–10.9 years), 4 404 and 1 637 participants developed dementia and Parkinson’s disease, respectively. Glucosamine intake was not associated with incident dementia or Parkinson’s disease. In fully adjusted models, the hazard ratios associated with glucosamine intake were 1.06 [95% confidence interval (CI): 0.99, 1.14] for dementia and 0.97(95% CI: 0.86, 1.09) for Parkinson’s disease. In the subsample, similar results were found as the frequency of reported glucosamine use over multiple dietary surveys was associated with neither of the 2 conditions.

Conclusions:

Habitual supplementation of glucosamine was not associated with incident dementia or Parkinson’s disease.

02 Jan 2024·Archives of animal nutrition

Inclusion of a Bacillus -based probiotic in non-starch polysaccharides-rich broiler diets

Article

Author: Sandvang, Dorthe ; Pachocka, Marta ; Zentek, Jürgen ; Duangnumsawang, Yada ; Józefiak, Damian ; Goodarzi Boroojeni, Farshad

This study examined the effects of a 3-strain Bacillus-based probiotic (BP; Bacillus amyloliquefaciens and two Bacillus subtilis) in broiler diets with different rye levels on performance, mucus, viscosity, and nutrient digestibility. We distributed 720 one-d-old female broilers into 72 pens and designed nine diets using a 3 × 3 factorial approach, varying BP levels (0, 1.2 × 10⁶, and 1.2 × 10⁷ CFU/g) and rye concentrations (0, 200, 400 g/kg). On d 35, diets with 200 or 400 g/kg rye reduced broiler weight gain (BWG). Diets with 400 g/kg rye had the highest FCR, while rye-free diets had the lowest (p ≤0.05). Adding BP increased feed intake and BWG in weeks two and three (p ≤0.05). It should be noted that the overall performance fell below the goals of the breed. Including rye in diets reduced the coefficient of apparent ileal digestibility (CAID) for protein, ether extract (EE), calcium, phosphorus, and all amino acids (p ≤0.05). Rye-free diets exhibited the highest CAID for all nutrients, except for methionine, EE, and calcium, while diets with 400 g/kg of rye demonstrated the lowest CAID (p ≤0.05). BP in diets decreased phosphorus CAID (p ≤0.05). Diets containing 1.2 × 10⁷ CFU/g (10X) of BP exhibited higher CAID of methionine than the other two diets (p ≤0.05). Diets containing 10X of BP showed higher CAID of cysteine than diets with no BP (p ≤0.05). Ileal viscosity increased as the inclusion level of rye in the diets increased (p ≤0.05). The ileal concentration of glucosamine in chickens fed diets with 400 g/kg of rye was higher than in those fed diets with no rye (p ≤0.05). Furthermore, ileal galactosamine concentrations were elevated in diets with 200 and 400 g/kg of rye when compared to rye-free diets (p ≤0.05). However, BP in diets had no impact on ileal viscosity, galactosamine, or glucosamine (p > 0.05). In conclusion, the applied Bacillus strains appeared to have a limited capacity to produce arabinoxylan-degrading enzymes and were only partially effective in mitigating the negative impacts of rye arabinoxylans on broilers.

News (Medical) associated with Glucosamine Hydrochloride

26 Mar 2024

·www.prnewswire.com

CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews

Pet Hip and Joint Health Chews and Pet Calming Care Chews improve the physical and emotional well-being of dogs SAN DIEGO, March 26, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, proudly announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the industry-leading +PlusCBD lineup are now available nationwide at select retailers and from our website at . Continue Reading Pet Chews Available Now! The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBD™Pet has developed a premium CBD chew with the mission of providing the highest quality ingredients and best-in-class health and nutrition for cherished family members - our pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, our chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of your loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in your devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, our chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions. Joseph Dowling, CEO of CV Sciences, commented on the significance of the NASC safety study, stating, "The NASC's comprehensive safety study further validates CBD supplements to promote the health and wellness of our family pets. Our long-standing commitment to quality and safety will provide pet owners with products they can trust. We are immensely proud to offer CBD chews that not only meet our rigorous standards, but also exceed industry benchmarks for safety and efficacy." +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of our human consumers, including +PlusCBD™ Reserve Collection Extra Gummies, +PlusCBD™ Reserve Collection Sleep Gummies, +PlusCBD™ Daily Balance THC-Free Gummies and Softgels and +PlusCBD™ Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives. For more information, please visit +PlusCBD or CV Sciences. About CV Sciences, Inc. CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company's Cultured Foods™ brand provides a variety of 100% plant-based food products. Committed to crafting nutritious and flavorful alternatives, Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. CV Sciences, Inc. has primary offices and facilities in San Diego, California, and Warsaw, Poland. The Company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics. Additional information is available from OTCMarkets.com or by visiting . Media Contact: Alexis Isaacs [email protected] SOURCE CV Sciences, Inc.

18 Oct 2023

·www.outsourcing-pharma.com

Bioiberica excited to welcome pharma stakeholders to its hometown for CPHI

“CPHI is always a fantastic opportunity to connect with customers – new and old – but the excitement has been taken up a notch this year as we welcome key stakeholders from across the global pharmaceutical landscape to our hometown, Barcelona,” said Luis Solera, CEO at Bioiberica. The life science company says it is committed to ‘improving the health and well-being of people, animals and plants’ and is excited to participate in the event. It will be showcasing its investment in scientific research, sustainable development and strategic partnerships for a more resilient future, it says. Alongside its active pharmaceutical ingredient (API) portfolio, the company will present the latest research for its mobility, digestive and skin health branded ingredients. Attendees will also have the opportunity to explore Bioiberica’s newfound focus on advanced wound care which is describes as ‘a captivating area of research in the medical nutrition arena’. Also under the spotlight for the first time, Bioiberica will share scientific data set to unlock a new world of co-innovation possibilities. Essential APIs The company will exhibit its essential APIs – chondroitin sulfate and glucosamine for the symptomatic treatment of osteoarthritis, thyroid for endocrinology and its flagship ingredient, Heparin. Visitors to the company’s stand will get the chance to see the latest research supporting the efficacy of its branded ingredients – Collavant n2 (native (undenatured) type 2 collagen), Mobilee (hyaluronic acid matrix ingredient) for joint health and mobility, Dermial (hyaluronic acid matrix ingredient) for skin health and DAOgest (diamine oxidase enzyme) for histamine intolerance. googletag.cmd.push(function () { googletag.display('text-ad1'); }); With sustainability top of the agenda for the pharmaceutical industry, Bioiberica will highlight the potential of its latest sustainability initiatives and how they’re helping to enhance its customers’ green credentials in the face of mounting pressures. Climate neutrality Attendees can connect with Bioiberica’s experts to learn more about its circular bioeconomy model, targets to obtain 100% renewable electricity by 2024 and 30% less GHG emissions by 2030, and ambitious plans to achieve climate neutrality by 2050. Solera added: “Progression in the healthcare space hinges on three key pillars: science, sustainability and strategic partnership. CPHI offers us a platform to highlight the substantial strides we’ve made to strengthen these foundations and showcase how we’re supporting our customers in addressing some of the most pressing challenges facing the pharmaceutical industry. Visitors are warmly invited to our booth where we look forward to fostering innovative ideas together.” Meet Bioiberica at CPHI on stand 7P20 to learn more about the company's APIs and ingredients for human health.

14 Nov 2006

·www.biospace.com

SCOLR Pharma, Inc. Partner Introduces Three New Products Based On SCOLR Technology

BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (AMEX: DDD) today announced the introduction of three once-daily CDT® based private label products -- Glucosamine/Chondroitin Sodium Free, Glucosamine, and Glucosamine/Chondroitin/MSM -- by its alliance partner, The Perrigo Company. The introduction took place at the Private Label Manufacturers Association 2006 PLMA Trade Show in Rosemont, Illinois, earlier this week.

100 Deals associated with Glucosamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D08022	Glucosamine Hydrochloride	M01AX05	DB01296

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Osteoarthritis	CN	Rottapharm SpA	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	CN	Jiangsu Hansoh Pharmaceutical Co. Ltd.	04 Nov 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00691678 (CTgov)	Phase 2	Breast Cancer \| Arthralgia	53	Glucosamine+Chondroitin	xkcifldijb(khuirztlob) = dyxxfohfli oicqicbvyy (doscoyetdu, qrnvkpuwcy - nsfkmluoxv) View more	-	08 Nov 2022
Pubmed \| J Oral Maxillofac Surg	Not Applicable	Osteoarthritis	-	Oral Glucosamine Hydrochloride + Hyaluronate Sodium Intra-Articular Injection	qgfyrtkczl(jmiqjliyhj) = wwlygjfopd dvyhrvaztn (kygeyzgizh )	Positive	01 Oct 2018
				Hyaluronate Sodium Intra-Articular Injection	qgfyrtkczl(jmiqjliyhj) = tmznbqayfu dvyhrvaztn (kygeyzgizh )
MOVES (EULAR2014)	Phase 4	Osteoarthritis, Knee	606	Combined glucosamine hydrochloride and chondroitin sulfate (GH+CS)	gcughfnypc(vxwjhhznom) = awqagtpakq jvndhbhhuf (kxihzmijba )	Positive	11 Jun 2014
				Celecoxib (CE)	gcughfnypc(vxwjhhznom) = tstzwsmglj jvndhbhhuf (kxihzmijba )
GLUCOSAMINE-CHONDROITIN SULFATE (EULAR2013)	Not Applicable	Low Back Pain	-	Glucosamine-chondroitin sulfate (GCS)	bybodankie(acnszoypme) = ljwhdipqnq jcvzpkgxjy (msarvwmpvy ) View more	Positive	12 Jun 2013
ARVO2009	Not Applicable	Glaucoma	21	Glucosamine supplementation	genlmihddx(ugxcqvukuj) = imiuoqeazz dyxtendtma (xrcpmtlabi, +/ - 3.67)	-	01 Apr 2009
				No glucosamine supplementation	genlmihddx(ugxcqvukuj) = vfnuzgrkno dyxtendtma (xrcpmtlabi, +/ - 3.29)
EULAR2006	Not Applicable	Osteoarthritis	-	Glucosamine-sulfate and omega-3 fatty acids	ckigrgjaxk(qitpsbciqm) = oebpxpltxa tccivajshy (cnlsxkreqe ) View more	-	21 Jun 2006
				Placebo	ckigrgjaxk(qitpsbciqm) = lqbfobihjr tccivajshy (cnlsxkreqe ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis